UR 1505
Alternative Names: UR-1505Latest Information Update: 18 Jan 2018
At a glance
- Originator Uriach
- Developer Palau Pharma
- Class Anti-inflammatories; Antipsoriatics; Salicylates; Small molecules
- Mechanism of Action Immunomodulators; Lymphocyte inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Transplant rejection